Glioblastoma stem cell vaccine to help prevent and control brain cancer
Official title: Glioblastoma stem cell vaccine for the prevention and control of glioblastoma
Funded at North Carolina Agri & Tech St Univ · NIH-11399170 · Data updated 2026-11-12
A vaccine approach using glioblastoma stem cells is being explored to prevent and treat glioblastoma in patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina Agri & Tech St Univ NIH-funded |
| Lab location | 1 site (Greensboro, United States) |
| Project start | August 5, 2025 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $138,189 |
| NIH project number | 5R16NS147983-02 |
| Project ID | NIH-11399170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma or those at risk of recurrence could be candidates in future translational steps.
✕Less likely to help
Patients with glioblastoma not eligible for vaccine trials or with certain contraindications may not benefit.
What this research studies
This project tests a novel vaccine designed from glioblastoma stem-like cells to boost the body's immune response against brain tumors. Researchers will use animal models to study how the vaccine triggers T cells to attack cancer cells and to understand the immune mechanisms at work. The goal is to determine if the vaccine can prevent tumor growth and improve control of the disease in a setting that mimics human GBM. If the approach is successful, it could pave the way for future clinical trials in patients with glioblastoma.
Why it matters
Potential benefit: If successful, patients with glioblastoma could receive a new vaccine that helps the immune system attack the cancer and potentially extend survival.
How similar studies have gone: Preliminary data suggest a strong immune response and protection signals in animal models, though human results are not yet established.
Where this research is happening
-
North Carolina Agri & Tech St Univ
Greensboro, United States Active
Researchers
- Principal investigator: Saha, Dipongkor — North Carolina Agri & Tech St Univ
- Study coordinator: Saha, Dipongkor
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.